GLP-1 and Hormone Optimization Aren't Competing Treatments. Here's Why They're Better Together
You started a GLP-1 medication and the first few months worked exactly like you hoped. The weight came down steadily, your appetite finally felt manageable, and you started to believe this was the tool you'd been missing. Then, somewhere around month three or four, things slowed. The scale barely moved even though nothing about your dose or your habits had changed. You still felt tired. Your clothes fit differently in a way that wasn't just about weight, more like you'd gotten smaller but softer at the same time.
If your doctor's answer was to increase the dose or simply wait it out, you were only getting part of the picture. GLP-1 medications are genuinely effective, but they only treat one system. For a lot of people over 40, there's a second system running in the background that a GLP-1 was never designed to touch, and when it's been quietly declining, it limits how well the medication can work.
Two Different Systems, Treated Like One Problem
GLP-1 medications like semaglutide and tirzepatide work primarily on appetite and satiety signaling. They slow digestion, act on receptors in the brain that control hunger, and make it dramatically easier to eat less without the constant mental fight that usually comes with it. That's a real, mechanistically distinct effect, and it's why these medications work as well as they do.
But appetite regulation is not the same system that determines your body composition, your resting metabolic rate, or where your body chooses to store fat. That's largely governed by sex hormones — testosterone in men, estrogen in women — and by midlife, those hormone levels are often already declining independently of anything happening with weight. A GLP-1 can turn down your appetite perfectly and still be working against a body that's biochemically primed to lose muscle instead of fat, or to hang onto visceral fat regardless of how few calories come in.
What Declining Testosterone Does to the Equation
Testosterone is one of the primary signals that tells your body to build and preserve muscle. A systematic review and meta-analysis of randomized controlled trials in older men with low testosterone found that testosterone therapy produced meaningful increases in lean mass and reductions in fat mass compared to placebo across the pooled trials. Muscle is metabolically active tissue, so a man entering GLP-1 treatment with already-low testosterone is starting from a disadvantage: less muscle to begin with, and less hormonal signal telling his body to protect the muscle he has while he's losing weight.
What Declining Estrogen Does to the Equation
For women, the mechanism runs through estrogen rather than testosterone, but the effect is similar. Research following women through the menopausal transition has found a shift toward increased visceral fat storage and reduced energy expenditure as estrogen declines, independent of any change in diet or activity. A separate cohort study following postmenopausal women found that current users of menopausal hormone therapy carried significantly less total and visceral fat than women who had never used it, and that this advantage was present only during active use. It's an observational finding, not a randomized trial, so it can't prove hormone therapy caused the difference on its own, but it points in the same direction as the mechanism: estrogen decline changes where and how the body stores fat, on top of anything a GLP-1 is doing.
What Happens When You Address Both at Once
This isn't just a theoretical argument. A 2025 Mayo Clinic study followed 120 postmenopausal women with overweight or obesity, comparing those taking tirzepatide alongside menopausal hormone therapy to those taking tirzepatide alone. Over twelve months or more, the combined group lost roughly 35 percent more weight than the tirzepatide-only group. The researchers were direct about the limitation: this was an observational comparison, not a randomized trial, so factors like healthier baseline habits or better sleep among hormone therapy users could be contributing to part of the difference. It's not proof of a guaranteed effect, but it's a meaningful signal in a population where that combination is rarely even discussed as an option.
The picture in men is earlier and less settled, but moving in an interesting direction from the other side. Early data presented at a 2026 endocrinology meeting, not yet published in a peer-reviewed journal, found that GLP-1 therapy modestly raised testosterone levels in obese men with hypogonadism, plausibly because reducing body fat reduces the conversion of testosterone into estrogen that happens in fat tissue. That's a real and encouraging mechanism, but it's preliminary conference-level data, and it doesn't mean testosterone optimization becomes unnecessary. If levels are still low after fat loss, that's still worth addressing directly rather than assuming the GLP-1 will finish the job on its own.
A Familiar Pattern
Consider a patient in their late forties who started a GLP-1 medication and had a strong first few months, then hit a wall around month four. Weight loss nearly stopped, energy stayed low, and strength in the gym was quietly declining despite consistent effort. A full hormone panel, something that hadn't been part of the original workup, showed sex hormone levels at the low end of the range, technically "normal" on a standard lab report but far from optimal. Hormone optimization was added alongside the existing GLP-1 treatment, without changing the medication itself. Over the following months, both the scale and body composition began moving again, and the fatigue that had been written off as "just getting older" improved as well. That's one composite pattern, not a guarantee of how any individual will respond. But it's a common enough story that it's worth checking for before assuming a plateau means the medication has stopped working.
Who Should Consider This
This isn't a case for adding hormone therapy to every GLP-1 prescription automatically. It's worth a conversation if you're already on a GLP-1 and your results have plateaued despite consistent adherence, if you're losing weight but also losing strength or energy faster than seems reasonable, or if you're starting a GLP-1 and want to build in protection for your muscle and metabolic rate from day one rather than trying to recover it later. A full hormone panel, not just a symptom checklist, is the starting point either way.
What a Realistic Timeline Looks Like
If hormone optimization is added alongside an existing GLP-1, early changes in energy and how clothes fit are often noticeable within four to six weeks, though that's subjective and varies by person. Measurable shifts in body composition, tracked properly rather than just by the scale, typically take two to three months to show clearly. Hormone levels and relevant labs should be rechecked periodically throughout treatment, both to confirm the optimization is working and to make sure it stays in a safe, appropriate range. This isn't a one-time fix. It's an ongoing process of monitoring two systems that influence each other, not just one.
GLP-1 medications and hormone optimization aren't competing for the same job. One manages appetite. The other manages the muscle, metabolism, and fat distribution underneath it. Addressing only one usually means leaving real results on the table.
If you're on a GLP-1 and feel like your results have stalled, or you're thinking about starting one and want to protect your muscle and metabolism from the beginning, it's worth having a real conversation about what your hormones are doing underneath the medication.
Have you noticed your results slow down on a GLP-1 even though nothing else changed?
A free consultation is a good place to start that conversation, no commitment required, just a chance to look at the full picture together.
References
Krause Neto W et al., Age (Dordrecht), 2015 — PMID: 25637335 (meta-analysis of RCTs)
Lovejoy JC et al., International Journal of Obesity, 2008 — PMID: 18332882
Papadakis GE et al. (OsteoLaus Cohort), Journal of Clinical Endocrinology & Metabolism, 2018 — PMID: 29596606 (observational cohort, not RCT)
Castaneda R, Hurtado Andrade MD et al., The Lancet Obstetrics, Gynaecology & Women's Health, 2025 (observational comparison, not RCT; PMID not yet available)
Muhammad J, Abedi H, Natesh P, presented at ENDO 2026 (Endocrine Society annual meeting), June 2026 — conference abstract, not yet peer-reviewed; no PMID available
This content is for educational purposes only and does not constitute medical advice. GLP-1 receptor agonists and hormone optimization therapies carry individual risks, contraindications, and monitoring requirements, and combined use should only be pursued under the guidance of a qualified physician following a full evaluation of your health history and lab work. Individual results vary, and no outcome is guaranteed. Dr. Wilcox is licensed to practice in Texas and Arizona.
